Akexis Company Profile

Background

Mission and Vision

Akexis is a biopharmaceutical company dedicated to developing transformative cancer therapeutics, with a primary focus on addressing cancer cachexia—a debilitating condition affecting 80% of late-stage cancer patients and contributing directly to 30% of cancer-related deaths. The company's mission is to develop the first therapy that addresses the root cause of cancer cachexia, aiming to empower patients with advanced cancer to endure anti-tumor treatments, achieve better survival outcomes, and experience an improved quality of life. Akexis envisions a future where advanced cancer is no longer defined by limited treatment options or devastating side effects, but by hope, resilience, and survivability.

Industry Significance

Cancer cachexia remains a significant unmet need in oncology, with no FDA-approved treatments currently available. By targeting the underlying immune system dysfunction that drives cachexia, Akexis is poised to revolutionize the standard of care for late-stage cancer patients, offering new hope and improving survival outcomes.

Key Strategic Focus

Core Objectives

Akexis is committed to developing therapies that address the underlying causes of cancer cachexia, focusing on immune system dysfunction to improve patient outcomes in late-stage cancer.

Areas of Specialization

The company specializes in immunomodulation therapies aimed at reversing cachexia and enhancing the efficacy of existing cancer treatments.

Key Technologies Utilized

Akexis employs small molecule technology in its lead candidate, AKX001, an immunomodulator designed to reduce inflammatory cytokines and STAT3 activation, thereby preserving tissue integrity and strengthening immune defense.

Primary Markets Targeted

The primary market includes late-stage cancer patients, particularly those suffering from cachexia, with a focus on the United States and other regions with high cancer incidence rates.

Financials and Funding

Funding History

Specific details regarding Akexis's total funds raised and recent funding rounds are not publicly disclosed.

Notable Investors

Information about notable investors in Akexis is not publicly available.

Utilization of Capital

The capital raised is intended to support the development of Akexis's therapeutic pipeline, including advancing clinical trials for AKX001, and to expand the company's research and development capabilities.

Pipeline Development

Key Pipeline Candidates

AKX001: An immunomodulator targeting cancer cachexia, currently in early stages of development.

Stages of Development

AKX001 is in the preclinical phase, with plans for clinical trials pending regulatory approvals.

Target Conditions

The primary target condition is cancer cachexia, with potential applications in other cancer-related complications.

Anticipated Milestones

Key milestones include initiating clinical trials for AKX001 and publishing results from preclinical studies.

Technological Platform and Innovation

Proprietary Technologies

Akexis's proprietary technology centers on small molecule immunomodulators designed to reverse cachexia by modulating immune system dysfunction.

Significant Scientific Methods

The company employs advanced immunological assays to assess the impact of its therapies on immune system parameters and tissue integrity.

AI-Driven Capabilities

There is no publicly available information indicating the use of AI-driven capabilities in Akexis's research and development processes.

Leadership Team

Dr. Lingbing Zhang: Founder & CEO

Professional Background: Ph.D. in immunology from Jilin University; postdoctoral fellowship at Stanford School of Medicine focusing on immune dysregulation in cancer cachexia.

Contributions: Founded Yinuoke Ltd. in 2016 to develop therapies addressing immune dysfunction in cancer; established Akexis to advance immunomodulator programs for late-stage cancer patients.

Dr. Suzanne Kennedy: Co-Founder & COO

Professional Background: Ph.D. in microbiology and immunology from Virginia Commonwealth University Medical School; leadership roles at Bio-Path Holdings, GlycosBio, and ViuHealth.

Contributions: Drives clinical programs, R&D, and strategic partnerships at Akexis to develop groundbreaking cancer therapeutics.

Dr. Philip Bonomi, M.D.: Chief Medical Officer

Professional Background: Over 47 years as a medical oncologist and Professor of Medicine at Rush University Medical Center; expertise in lung cancer and mesothelioma.

Contributions: Oversees clinical strategy and development of Akexis's therapeutic pipeline, focusing on treatments for cancer cachexia.

Dr. Andrew Hendifar, M.D.: Principal Investigator

Professional Background: Associate Professor and Co-Director of the Hematology-Oncology Fellowship Program at Cedars-Sinai Medical School; Medical Director of Pancreatic Cancer and Gastrointestinal Oncology Disease Research at Cedars-Sinai Cancer Institute.

Contributions: Leads research on innovative therapies for pancreatic cancer, neuroendocrine tumors, and cancer cachexia; collaborates with Akexis on related studies.

Cassie Bernhardt: Chief Development Officer

Professional Background: Extensive experience in development and strategic fundraising; former Chief Development Officer at The University of Texas; founder of Impresa Advisors.

Contributions: Leads development strategies and external relations at Akexis to support innovative solutions for late-stage cancer treatment.

Leadership Changes

Dr. Suzanne Kennedy: Appointed Co-Founder and Chief Executive Officer on January 21, 2025.

Dr. Philip Bonomi, M.D.: Joined Akexis as Chief Medical Officer on February 11, 2025.

Competitor Profile

Market Insights and Dynamics

The oncology therapeutics market is experiencing significant growth, driven by increasing cancer incidence and the need for innovative treatments. Cancer cachexia remains a critical unmet need, with no FDA-approved therapies currently available.

Competitor Analysis

Akexis operates in a competitive landscape with several companies focusing on cancer cachexia and related conditions. Notable competitors include Arcellx, Inc., which is developing therapies for cancer cachexia, and Intra-Cellular Therapies, Inc., focusing on treatments for various psychiatric and neurological disorders. While these companies are not direct competitors in the cancer cachexia space, they represent the broader competitive environment in the biopharmaceutical industry.

Strategic Collaborations and Partnerships

Specific details regarding Akexis's strategic collaborations and partnerships are not publicly disclosed.

Operational Insights

Akexis differentiates itself through its focus on immunomodulation therapies targeting the root causes of cancer cachexia, aiming to improve patient outcomes and enhance the efficacy of existing cancer treatments.

Strategic Opportunities and Future Directions

Akexis is well-positioned to lead in the development of therapies for cancer cachexia, with plans to advance its lead candidate, AKX001, through clinical trials. The company's innovative approach offers significant potential to transform the standard of care for late-stage cancer patients.